Skip to main content
. 2009 Oct 8;158(6):1513–1526. doi: 10.1111/j.1476-5381.2009.00425.x

Figure 8.

Figure 8

Antagonism of ATP-stimulated IL-1β release from human whole and diluted blood. (A–D) Human whole blood or (E and F) human blood diluted 10-fold with phosphate-buffered saline was stimulated with LPS (1 µg·mL−1) for 80 min and then pre-incubated for 40 min with antagonist before measuring ATP-induced IL-1β release over a 30 min period. Studies were conducted at 37°C. The figures show the effect of (A) z-VAD, (B) GSK314181, (C) GSK361390 and (D) KN62 on ATP responses in whole blood. The effect of (E) GSK314181 or (F) GSK361390 is also shown in human blood diluted 10-fold with phosphate-buffered saline. Basal IL-1β release in the absence of antagonist is indicated on the X-ordinate as C. The data are the mean ± SEM of 3–6 separate experiments. GSK314181, 5-{[(3R)-3-amino-1-pyrrolidinyl]methyl}-2-chloro-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)benzamide; GSK361390, N-adamantan-1-ylmethyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide; IL-1β, interleukin-1β; KN62, 1-(N,O-bis-[5-isoquinoline-sulphonyl]-N-methyl-L-tyroyl)-4-phenyl-piperazine; LPS, lipopolysaccharide.